Table 3—

Case series with methicillin-resistant Staphylococcus aureus (MRSA) community-acquired pneumonia (CAP) patients published after 1985

First author [ref.]Total
Kallen 105Castaldo 106Centers for Disease Control 107Hageman 108Janvier 109Gonzalez 110Leroy 111
MRSA37/51 (73)7/7 (100)10/10 (100)15/17 (88)5/5 (100)12/14 (86)12/14 (86)98/118 (83)
Age yrs16 (<1–81)14.2 (0.8–16)17.5 (0.3–48)21 (0.25–62)NA13 (10–15)NANA
Male sex21/51 (41)5/7 (71)5/10 (50)8/17 (47)NA12/14 (86)NA51/99 (52)
Comorbidities27/48 (56)0/7 (0)1/10 (10)5/17 (29)NA2/14 (14)NA35/96 (36)
MRSA risk factors13/31 (42)NA4/10 (40)4/17 (24)NA1/14 (7)NA22/72 (31)
Influenza like symptoms22/47 (47)NA10/10 (100)17/17 (100)NA1/14 (7)NA50/88 (57)
Proven influenza infection11/33 (33)NA6/10 (60)12/17 (71)0/5 (0)1/14 (7)NA30/79 (38)
Necrotising pneumoniaNA7/7 (100)7/10 (70)4/16 (25)5/5 (100)NANA23/38 (61)
PVL production16/17 (94)NA10/10 (100)11/13 (85)5/5 (100)14/14 (100)NA56/59 (95)
Resistance to antibiotics#ERM 93LEV 50NAERM 100 CLN 20LEV 20ERM 100 CLN 91LEV 55NAERM 100NANA
Hospitalisation nm43/51 (84)7/7 (100)10/10 (100)16/17 (94)5/5 (100)14/14 (100)14/14 (100)109/118 (92)
ICU treatment34/43 (74)7/7 (100)NA13/16 (81)NA14/14 (100)NA68/80 (85)
Appropriate empirical therapy26/51 (51)NANA12/15 (80)NANA2/10 (20)40/76 (53)
Length of stay days16 (2–19)30 (5–53)NA13 (1–108)24 (5–42)24.5 (1–120)NANA
Death24/47 (51)3/7 (43)6/10 (60)5/17 (29)+1/5 (20)3/14 (21)3/14 (21)45/114 (39)
Symptom onset to death days4 (1–33)30 (5–51)3.5 (2–25)7 (3–73)NA5 (2–7)NANA
  • Data are presented as n/total patients (%) or median (range). The data for resistance to antibiotics is presented as per cent. PVL: Panton–Valentine leukocidin; ICU: intensive care unit; NA: not available/applicable; ERM: erythromycin; LEV: levofloxacin; CLN: clindamycin. #: strains were sensitive to linezolid, vancomycin, rifampin and gentamycin; : the remaining patients died in the emergency department or during transfer to another hospital; +: four out of five deceased patients had MRSA pneumonia.